Bromocriptine in systemic lupus erythematosus: a double-blind,randomized,placebo-controlled study

Abstract

The objective of this study was to investigate the efficacy and safety of bromocriptine (BRC) as an adjunct to conventional treatment in systemic lupus erythematosus (SLE). A prospective, doubleblind, randomized, placebo-controlled study compared BRC at a fixed daily dosage of 2.5 mg with placebo. Patients were followed for 2–17 months (mean 12.5 months). Disease activity was assessed using the SLE Disease Activity Index (SLEDAI), numbers of flares were recorded, and serum prolactin (PRL) levels were obtained at intervals during the study. Patients were allowed to take prednisone and immunosuppressive drugs.

Sixty-six patients with SLE entered the study. Thirty-six were treated with BRC, and 30 controls received placebo. Sixteen patients were removed from the study during the treatment period: five in each group left the study because of adverse effects, five became pregnant, and one patient who took placebo died with central nervous system lupus. Four patients in the BRC treatment group and three patients in the placebo group moved away or stopped coming for study visits for unknown reasons, and were lost to follow-up during the course.

At entry, serum PRL was (mean–s.d.) 24.8 ng/ml–18.4 in the BRC treatment group. This value fell to 5.8–9.0 after 12 months of treatment. Corresponding PRL values in controls were 23.7–22.1 pretreatment and 20.3–14 after 12 months. PRL levels in BRC-treated subjects were significantly lower than levels in control subjects after 3, 6, 9, and 12 months of treatment. The SLEDAI score on the fifth protocol visit was decreased significantly in the BRC group vs controls: 0.9–1.4 vs 2.6–4.5 (P < 0.05). Although the absolute number of flares in each group was similar, the mean number of flares/patient/month was decreased significantly in the BRC group compared to the control group (0.08–0.1 vs 0.18–0.2, P = 0.03).

Long term treatment with a low dose of BRC appears to be a safe and effective means of decreasing SLE flares in SLE patients.

Keywords

prolactin bromocriptine systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Berczi I . Prolactin, pregnancy and autoimmune diseases . J Rheumatol 1993; 20: 1095–1100 .

Walker SE , Allen SH , Hoffman RW , McMurray RW . Prolactin: a stimulator of disease activity in systemic lupus erythematosus . Lupus 1995; 4: 3–9 .

Besedovsky HO , Del Rey A . Immuno-neuro-endocrine interactions: facts and hypothesis . Endocr Rev 1996; 17: 64–102 .

Jara LJ et al. Hyperprolactinemia in systemic lupus erythematosus: association with disease activity . Am J Med Sci 1992; 303: 222–226 .

Jara-Quezada LJ , Graef A , Lavalle C . Prolactin and gonadal hormones during pregnancy in systemic lupus erythematosus . J Rheumatol 1991; 18: 349–353 .

Lavalle C et al. Correlation study between prolactin and androgens in male patients with systemic lupus erythematosus . J Rheumatol 1987; 14: 268–272 .

McMurray R et al. Prolactin influences autoimmune disease activity in the female B/W mouse . J Immunol 1991; 147: 3787–3790 .

Gutiérrez MA et al. Prolactin and systemic lupus erythematosus: prolactin secretion by lymphocytes and proliferative (autocrine) activity . Lupus 1995; 4: 348–352 .

Larrea F et al. A bioactive 60-kilodalton prolactin species is preferentially secreted in cultures of mitogen-stimulated and nonstimulated peripheral blood mononuclear cells from subjects with systemic lupus erythematosus . J Clin Endocrinol Metab 1997; 82: 3664–3669 .

10.

Gutiérrez MA et al. Prolactin-induced immunoglobulin and autoantibody production by peripheral blood mononuclear cells from systemic lupus erythematosus and normal individuals . Int Arch Allergy Immunol 1996; 109: 229–235 .

11.

Brennan P et al. Allelic markers close to prolactin are associated with HLA-DRB1 susceptibility alleles among women with rheumatoid arthritis and systemic lupus erythematosus . Arthritis Rheum 1997; 40: 1383–1386 .

12.

Buskila D , Shoenfeld Y . Prolactin, bromocriptine, and autoimmune diseases . Isr J Med 1996; 32: 23–27 .

13.

Bravo G , Zazueta B , Lavalle C . An acute remission of Reiter's syndrome in male patients treated with bromocriptine . J Rheumatol 1992; 19: 747–750 .

14.

Weber G , Frey H . Treatment of psoriatic arthritis with bromocriptine . J Am Acad Dermatol 1987; 16: 388–389 .

15.

Hender LP , Bynke G . Endogenous iridocyclitis relieved during treatment with bromocriptine . Am J Opthalmol 1985; 109: 618–619 .

16.

McMurray RW , Weindensaul D , Allen SH , Walker SE . Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus . J Rheumatol 1995; 22: 2084–2091 .

17.

Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 1271–1277 .

18.

Bombardier C et al. Committee on prognosis studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients . Arthritis Rheum 1992; 35: 630–640 .

19.

Petri M et al. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study . Arthritis Rheum 1991; 34: 937–944 .

20.

Vance ML , Thorner MO . Prolactin: Hyperprolactinemic syndromes and management. In: DeGroot LJ (ed). Endocrinology. W.B. Saunders Co.: Philadelphia , 1989; 408-408.

21.

Nagy E et al. Immunomodulation by bromocriptine . Immunopharmacology 1983; 6: 231–243 .

22.

Bernton EW , Meltzer MS , Holaday JE . Suppression of macrophage activation and T lymphocyte function in hypoprolactinemic mice . Science 1988; 239: 401–404 .

23.

Neidhart M . Bromocriptine microcapsules inhibit ornithine decarboxylase activity induced by Freund's complete adjuvant in lymphoid tissues of male rats . Endocrinology 1989; 125: 2846–2852 .

24.

Riskind PN , Massacesi L , Doolittle RH , Hauser SL . The role of prolactin in autoimmune demyelination: suppression of experimental allergic encephalomyelitis by bromocriptine . Ann Neurol 1991; 29: 542–547 .

25.

Blank M , Palestine A , Nusenblant R , Shoenfeld Y . Down-regulation of autoantibody levels with cyclosporine and bromocriptine treatment in uveitis . Clin Immunol Immunophatol 1990; 54: 87–97 .

26.

Morikawa K , Oseko F , Morikawa S . Immunosuppressive property of bromocriptine on human B lymphocyte function in vitro . Clin Exp Immunol 1993; 93: 200–205 .

27.

Morikawa K , Oseko F , Morikawa S . Immunosuppressive activity of bromocriptine on human T lymphocyte function in vitro . Clin Exp Immunol 1994; 95: 514–518 .

28.

Blank M et al. Bromocriptine immunomodulation of experimental SLE and primary anti-phospholipid syndrome via induction of non-specific T suppressor cells . Cell Immunol 1995; 162: 114–122 .

29.

Neidhart M . Elevated serum prolactin or elevated prolactin/cortisol ratio are associated with autoimmune processes in SLE and other CTD . J Rheumatol 1996; 23: 476–481 .

30.

Miranda JM et al. Prolactin (PRL) and interleukin-6 (IL-6) in severe lupus glomerulonephritis . Arthritis Rheum 1997; 40: S106–S106 (abstract 455).

31.

Jara LJ et al. Prolactin and interleukin-6 in neuropsychiatric lupus erythematosus. Clin Rheumatol (in press).

32.

Rovensky J et al. Relationship between endocrine, immune and clinical variables in patients with systemic lupus erythematosus . J Rheumatol 1997; 24: 2330–2334 .